Jemperli can be prescribed at general hospitals in KOR

Immuno-oncology drug for endometrial cancer

Passes drug committees of SNUH, AMC, etc.

Receives additional approval as a first-line therapy… expands area

Jemperli, the first immuno-oncology option introduced to the field of endometrial cancer, can now be prescribed in general hospitals in Korea.

 

According to industry sources, GSK Korea’s PD-1 inhibitor Jemperli (dostarlimab) has passed the drug committee (DC) reviews of tertiary hospitals in Korea.

 

Including the Seoul National University Hospital and Seoul Asan Medical Center.

 

The company has been gradually expanding its prescribing area after receiving reimbursement for Jemperli in December last year.

 

While the number of hospitals that granted use of the drug is still small, GSK has been working to create an enabling environment for Jemperli prescriptions even before the reimbursement process, implementing an Expanded Access Program (EAP) in 15 major medical institutions in Korea.

 

In the multi-cohort Phase 1 GARNET study that was conducted on patients with recurrent or advanced solid tumors, Jemperli demonstrated efficacy with the Cohort A1 analysis results, which enrolled patients with recurrent or advanced dMMR/MSI-H endometrial cancer who progressed during or after platinum-based systemic chemotherapy.

 

The cohort was among the largest conducted for PD-1 inhibitor monotherapies in advanced dMMR/MSI-H endometrial cancer to date.

 

The primary efficacy outcome measures of the study were Objective Response Rate (ORR) and Duration Of Response (DOR) as determined by a Blinded Independent Central Review (BICR) according to (Response Evaluation Criteria Solid Tumors) RECIST v 1.1.

 

As a result of analyzing a total of 108 patients with a median follow-up of 16.3 months, Jemperli demonstrated durable antitumor activity with a manageable safety profile.

 

In the cohort, the ORR was 43.5% and the median DOR was not yet reached.

 

The Disease Control Rate (DCR) was 55.6%, and the proportions of responses lasting 6 and 12 months were 97.9% and 90.9%, respectively.

 

On the 7th, Jemperli was additionally approved as a first-line treatment in combination with platinum-based chemotherapy for patients with Mismatch Repair Deficient/Microsatellite Instability-High (dMMR/MSI-H) recurrent or advanced endometrial cancer.